Cancer genomic medicine in Japan and the roles of pharmacists

被引：1
|
作者：
Aomori, Tohru [1 ,2 ]
Sakurai, Hiroomi [2 ]
Nishihara, Hiroshi [3 ]
机构：
[1] Keio Univ, Div Hosp Pharm Sci, Fac Pharm, Tokyo, Japan
[2] Keio Univ Hosp, Dept Pharm, Tokyo, Japan
[3] Keio Univ, Keio Canc Ctr, Genom Unit, Sch Med, Tokyo, Japan
来源：
PHARMACOGENETICS AND GENOMICS | 2022年 / 32卷 / 06期
关键词：
cancer genomic medicine; precision medicine;
D O I：
10.1097/FPC.0000000000000476
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.
引用
收藏
页码：242 / 245
页数：4
相关论文
共 50 条
  • [31] Targeting tyrosine kinases in cancer The Converging Roles of Cytopathology and Molecular Pathology in the Era of Genomic Medicine
    Dumur, Catherine I.
    Idowu, Michael O.
    Powers, Celeste N.
    CANCER CYTOPATHOLOGY, 2013, 121 (02) : 61 - 71
  • [32] Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan
    Kuniko Sunami
    Yoichi Naito
    Eriko Aimono
    Toraji Amano
    Daisuke Ennishi
    Hidenori Kage
    Masashi Kanai
    Keigo Komine
    Takafumi Koyama
    Takahiro Maeda
    Sachi Morita
    Daisuke Sakai
    Shinji Kohsaka
    Katsuya Tsuchihara
    Takayuki Yoshino
    International Journal of Clinical Oncology, 2021, 26 : 1007 - 1007
  • [33] Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan
    Yamazaki, Haruhiko
    Kunisaki, Chikara
    Sugimori, Makoto
    Rino, Yasushi
    Saito, Aya
    ENDOCRINE, 2024, 85 (02) : 766 - 776
  • [34] Development of a Nationwide Genomic Screening Project (SCRUM-Japan) for the Establishment of Cancer Precision Medicine
    Goto, Koichi
    ANNALS OF ONCOLOGY, 2017, 28 : 19 - 19
  • [35] Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).
    Ohashi, Kadoaki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Ohe, Yuichiro
    Shimokawaji, Tadasuke
    Kataoka, Yuki
    Kodani, Masahiro
    Sekine, Akimasa
    Saeki, Sho
    Furuya, Naoki
    Seto, Takashi
    Yokoyama, Takuma
    Shingyoji, Masato
    Hattori, Yoshihiro
    Kim, Young Hak
    Tsuchihara, Katsuya
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Pharmacists' roles in cancer pain control: A model in developing China
    Zhang, Ye
    Wang, Yan
    Xiao, Zhijun
    Xu, Feng
    Research in Social & Administrative Pharmacy, 2015, 11 (03): : E144 - E145
  • [37] EXPANDED ROLES FOR PHARMACISTS
    BRODIE, DC
    KNOBEN, JE
    WERTHEIM.AI
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 1973, 37 (04) : 591 - 600
  • [38] Roles of Cardiology Pharmacists
    Yamaguchi, Hiroki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2016, 136 (08): : 1121 - 1123
  • [39] PHARMACISTS ROLES REVISITED
    GRIFFENHAGEN, GB
    JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, 1976, 16 (10): : 545 - 545
  • [40] Implementation of genomic medicine for lung cancer
    Kage, Hidenori
    CANCER SCIENCE, 2025, 116 : 137 - 137
12345